To answer the question of whether quality - specifically, uncorrected vision, astigmatism, visual rehabilitation, and safety - is sacrificed when M-SICS is performed instead of phaco, Sanduk Ruit, MD, Geoffrey Tabin, MD, David F. Chang, MD, and colleagues conducted the first prospective, randomized trial of phaco versus M-SICS in a charity camp population.